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A b s t r a c t
The metabolic syndrome (MetS) confers an 
increased risk for diabetes and cardiovascular 
disease. Although high-sensitive C-reactive protein 
(hsCRP) concentrations are higher and adiponectin 
concentrations lower in MetS, there is no reliable 
biochemical measure that can capture its various 
features. We evaluated whether hsCRP, adiponectin, 
or the ratio of adiponectin or its oligomers, especially 
the high-molecular-weight (HMW) oligomer, to hsCRP 
predict MetS in 123 subjects with MetS compared 
with that in 91 healthy control subjects. MetS subjects 
had significantly higher hsCRP levels and lower total 
adiponectin and oligomer levels relative to control 
subjects (P < .0001). The HMW/total adiponectin and 
adiponectin/CRP ratios were significantly lower in 
MetS subjects than control subjects (P < .005). The 
odds ratio (OR) of MetS using the 75th percentile 
cutoff for CRP was 3.8 (95% confidence interval [CI], 
2.1-6.8) and equivalent to low total adiponectin (OR, 
2.5; 95% CI, 1.3-4.5), its oligomers, or the adiponectin/
hsCRP ratio (OR, 2.6; 95% CI, 1.5, 4.8). Thus, 
measurements of CRP, adiponectin, or its oligomers 
provide robust biomarkers for predicting MetS.
The metabolic syndrome (MetS) is a cluster of cardio-
vascular risk factors, which includes abdominal obesity, 
hypertension, hyperglycemia, dyslipidemia, and insulin resis-
tance.1 In the United States, 1 in 4 people has MetS, and it 
is associated with an increased propensity for diabetes and 
cardiovascular disease.
Inflammation is pivotal to atherosclerosis. Recently, 
several lines of evidence implicate inflammation in the 
development of insulin resistance and MetS.2 Furthermore, 
abundant evidence has emerged demonstrating that high 
concentrations of high-sensitive C-reactive protein (hsCRP) 
are associated with MetS and may predict diabetes and car-
diovascular events, independent of traditional risk factors. 
It has also been suggested that CRP may be included in the 
criteria for MetS.3 Concentrations of CRP predict increased 
cardiovascular events in MetS and diabetes.4-7 In addition, 
CRP concentrations correlate strongly with adiposity and 
insulin resistance.8-10
The adipocyte-derived hormone adiponectin is an impor-
tant link among adiposity, type 2 diabetes, and cardiovascular 
disease.11 Circulating adiponectin concentrations are reduced 
in humans with obesity, type 2 diabetes, and coronary artery 
disease.12-14 Adiponectin-deficient mice exhibit diet-induced 
insulin resistance.15,16 In humans, low plasma adiponectin con-
centrations independently predict the development of type 2 
diabetes and myocardial infarction.17,18 Hypoadiponectinemia 
is also associated with MetS.19 Furthermore, adiponectin 
concentrations have been found in a number of studies to 
be inversely associated with systemic inflammation, as evi-
denced by increased concentrations of hsCRP.20
In the circulation, adiponectin is found in 3 major forms: 
as trimers (low molecular weight [LMW]), as hexamers 
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(medium molecular weight [MMW]), and as larger multi-
mers of 12 to 18 subunits (high molecular weight [HMW]).21 
HMW adiponectin, but not the MMW form, lowers blood 
glucose concentrations in adiponectin-deficient mice.11,21 
Moreover, thiazolidinedione- and gastric bypass surgery–
mediated improvements in insulin sensitivity are more closely 
associated with changes in HMW adiponectin than with total 
adiponectin concentrations.22,23 HMW adiponectin concentra-
tions are also closely related to improvements in high-density 
lipoprotein cholesterol (HDL-C) following weight loss.23,24
Developing a robust biomarker that can predict MetS 
instead of examining individual features will be important 
from a population standpoint in screening, monitoring the 
natural history of the disease, and measuring the response to 
therapeutic interventions. However, the ability of HMW adi-
ponectin to detect the presence of MetS or to predict individual 
MetS components has not been specifically assessed. Thus, 
while hsCRP concentrations are higher in MetS and adiponec-
tin concentrations are lower in MetS and both seem to be 
highly relevant to the 2 major sequelae of MetS, diabetes and 
cardiovascular disease, existing studies have not examined the 
predictive power of these markers alone and/or in combination 
for MetS. In the present study, therefore, we tested whether 
CRP, adiponectin, or both HMW and LMW adiponectin/CRP 
ratios are valid and robust markers that predict MetS.
Materials and Methods
Subjects
All subjects were recruited following informed con-
sent at the University of California Davis Medical Center, 
Sacramento. MetS was assessed in 214 adult subjects by mod-
ified criteria of the National Cholesterol Education Program 
Adult Treatment Panel III.25
Subjects had to have 3 or more of the following 5 features 
to be classified as having MetS: (1) Central obesity was mea-
sured by waist circumference, being greater than 40 inches in 
men and greater than 35 inches in women. (2) Elevated fasting 
triglyceride levels were categorized as greater than or equal to 
150 mg/dL (1.7 mmol/L). (3) A low HDL-C level was defined 
as less than 40 mg/dL (1.0 mmol/L) in men and less than 50 
mg/dL (1.3 mmol/L) in women. (4) High blood pressure was 
defined as a systolic blood pressure greater than 130 mm Hg 
and a diastolic blood pressure greater than 85 mm Hg. (5) An 
elevated fasting glucose level was defined as a concentration 
greater than or equal to 100 mg/dL (5.6 mmol/L). Exclusion 
criteria were as follows: smoking; use of lipid-lowering drugs 
or drugs known to effect lipid metabolism; diabetes and/or 
hypertension treated with drug therapy; aspirin therapy; anti-
inflammatory drugs; liver, renal or uncompensated metabolic 
or hormonal disorders; infection; cancer; recent major surgery 
or illness; an hsCRP level of more than 10 mg/L; and/or an 
increased WBC count.
Anthropometric Measurements
Weight, waist circumference, height, and systolic and 
diastolic blood pressure were measured according to standard 
procedures by trained clinical research personnel. The body 
mass index (BMI) was calculated as weight (in kg) divided 
by height (in m2).
Biochemical Measurements
The lipid profile and glucose levels were measured in 
the clinical pathology laboratory using standard laboratory 
methods. Insulin was measured by radioimmunoassay (Linco, 
St Louis, MO; coefficient of variation [CV], <9%). HOMA-
IR (homeostasis model assessment for insulin resistance), a 
marker of insulin sensitivity, was assessed as described previ-
ously.26 The hsCRP levels were measured using an automated 
immunoassay (Beckman Coulter LX PRO, Beckman Coulter, 
Fullerton, CA), which has an interassay and intra-assay CV 
of less than 7%.27 Adiponectin multimers were measured in 
duplicate by enzyme-linked immunosorbent assay (ALPCO 
Diagnostics, Salem, NH), a method recently validated against 
Western blot analysis.28 In addition to measuring total adi-
ponectin, the enzyme-linked immunosorbent assay uses a 
protease treatment to digest the LMW and MMW adiponec-
tin, enabling HMW adiponectin to be measured. MMW 
and LMW adiponectin are calculated by subtraction. In our 
laboratory, the interassay CVs for total and HMW adiponectin 
were 9.8% and 12.9%, respectively. The intra-assay CVs for 
each were less than 6.9% and less than 10%, respectively.
Statistical Procedures
Statistical procedures were performed by a general clini-
cal research center biostatistician using SAS software, version 
9.1 (SAS Institute, Cary, NC). All continuous variables were 
first assessed for normality using the Kolmogorov-Smirnov 
test. Comparisons between groups for continuous variables 
were performed using a t test or its nonparametric equivalent 
(Mann-Whitney or Wilcoxon rank sum test), as appropri-
ate. Categorical variables were compared between groups 
by using the Fisher exact test. Relationships of total adi-
ponectin, HMW, MMW plus LMW adiponectin, SA (HMW 
adiponectin/total adiponectin ratio), hsCRP, and the number 
of MetS components were assessed by 1-way analysis of 
variance (ANOVA) or the nonparametric Kruskal-Wallis test. 
Correlations between continuous variables were assessed by 
using the nonparametric Spearman rank. Linear regression 
was used to plot the relationships of CRP, total adiponectin, 
and HMW or MMW plus LMW adiponectin. In all cases, the 
level of significance was set at a P value of less than .05.
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Multiple logistic regression was used to study the pre-
dictive value of total adiponectin, HMW, MMW plus LMW 
adiponectin, SA, and hsCRP. Receiver operating characteristic 
(ROC) curves were generated to evaluate the ability of the 
biochemical markers to discriminate subjects with and with-
out MetS. The areas under the ROC curves were compared by 
using a nonparametric approach. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated from the estimates 
provided in the models.
Results
We studied 123 subjects with MetS and 91 healthy con-
trol subjects zTable 1z. As expected, the MetS group had sig-
nificantly higher weight, BMI, waist circumference, glucose 
levels, blood pressure readings, and triglyceride levels and 
lower concentrations of HDL-C than the non-MetS group. 
In a subset of 172 subjects, fasting plasma insulin concentra-
tions were also determined so that HOMA-IR, a measure of 
insulin resistance, could be calculated. As expected, plasma 
insulin concentrations and HOMA-IR were significantly 
higher in the MetS group than in the non-MetS group (P < 
.0001 for both).
The hsCRP concentrations were significantly higher in 
MetS subjects than in non-MetS subjects (45% increase; P 
< .001). The levels of total adiponectin and HMW and other 
forms of adiponectin (MMW + LMW, SA) were signifi-
cantly lower in MetS subjects than in control subjects (P < 
.0001). There was a significant inverse correlation between 
hsCRP and adiponectin concentrations and its oligomers 
(adiponectin and hsCRP, Spearman r = –0.34; P < .0001; 
HMW adiponectin and hsCRP, r = –0.30; P < .0001; non-
HMW adiponectin and hsCRP, r = –0.35; P < .0001; and 
SA and hsCRP, r = –0.20; P = .0027). Because the hsCRP 
concentrations were higher and adiponectin concentrations 
lower in MetS, we examined the CRP/adiponectin ratio and 
the ratio of different adiponectin oligomers to CRP. There 
was a significant decrease in the adiponectin/CRP ratio 
in MetS subjects compared with that in control subjects 
(78% decrease; P < .0001). Similarly, the associations of 
the HMW adiponectin/CRP ratio and LMW plus MMW 
adiponectin/CRP ratio were also significantly decreased in 
MetS subjects zTable 2z.
Correlation of hsCRP and Adiponectin With Different 
Features of MetS
When subjects were grouped according to the number of 
MetS components (0-5), concentrations of total adiponectin, 
HMW, MMW plus LMW, SA, and ratios significantly and 
progressively decreased and hsCRP showed a progressive 
and highly significant increase with an increasing number of 
features of MetS zTable 3z.
ORs for MetS Using the 75th Percentile Cutoff for CRP 
and the 25th Percentile for Adiponectin
By using the 75th percentile cutoff for CRP and the 25th 
percentile cutoff for adiponectin, ORs were computed for hav-
ing MetS zTable 4z. The OR of having MetS by using the 75th 
percentile cutoff for CRP was 3.8 and was equivalent to low 
adiponectin concentrations (OR, 2.5), the total adiponectin/
CRP ratio (OR, 2.6), HMW adiponectin/CRP (OR, 3.0), and 
zTable 1z
Descriptive Statistics for Study Groups*
Variable Metabolic Syndrome (n = 123) Control Subjects (n = 91) P
Sex (M/F) 47/76 36/55 .888†
Age (y) 51 ± 12 52 ± 12 .779
Waist circumference (cm) 110 ± 16 87 ± 10 <.0001‡
Weight (kg) 106 ± 25 87 ± 20 <.0001
BMI (kg/m2) 36 ± 6 30 ± 6 <.0001‡
Systolic BP (mm Hg) 131 ± 12 118 ± 10 <.0001‡
Diastolic BP (mm Hg) 84 ± 8 77 ± 9 <.0001‡
Glucose level (mg/dL) 105 ± 38 89 ± 12 .0136‡
Insulin level (µU/mL) 27.1 ± 3.1 17.9 ± 1.2 <.0001§
HOMA-IR 7.69 ± 1.20 4.09 ± 0.31 <.0001§
Total cholesterol level (mg/dL) 228 ± 47 228 ± 42 .99
HDL cholesterol level (mg/dL) 39 ± 9 51 ± 13 <.0001‡
LDL cholesterol level (mg/dL) 147 ± 37 151 ± 37 .50
Triglyceride level (mg/dL) 194 ± 12 122 ± 7 <.0001‡
BMI, body mass index; BP, blood pressure; HOMA-IR, homeostasis model assessment for insulin resistance.
* Data are given as mean ± SD. Laboratory values are given in conventional units; conversions to Système International units as follows: cholesterol, HDL, and LDL (mmol/L), 
multiply by 0.0259; glucose (mmol/L), multiply by 0.0555; insulin (pmol/L), multiply by 6.945; triglycerides (mmol/L), multiply by 0.0113.
† Fisher exact test.
‡ Wilcoxon rank sum test.
§ t test.
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the LMW plus MMW adiponectin/CRP ratio (OR, 3.0). The 
area under the curve for CRP (0.74) was equivalent to that of 
the adiponectin/CRP ratio (0.75), the adiponectin oligo-mers/
CRP ratio, and adiponectin alone (0.69) zFigure 1z. The sensi-
tivity at an hsCRP level of more than 3 mg/L was 73% (95% 
CI, 64%-80%), and the specificity was 64% (95% CI, 53%-
74%). The sensitivity of the adiponectin level at less than 6 
mg/L was 68% (95% CI, 59%-76%), and the specificity was 
66% (95% CI, 55%-76%). The sensitivity of an adiponectin/
CRP ratio of less than 2 was 69% (95% CI, 60%-77%), and 
the specificity was 68% (95% CI, 58%-78%).
Discussion
MetS seems to be a proinflammatory state characterized 
by increased concentrations of CRP. Several earlier stud-
ies have shown that high CRP concentrations predict the 
development of diabetes. CRP has been shown to impair 
insulin signaling.29 Although increased CRP concentrations 
correlate most strongly with adiposity and insulin resistance, 
CRP also correlates significantly with the other features of 
MetS.8-10 Furthermore, CRP concentrations predict increased 
cardiovascular events in MetS and in diabetes.4-7 The level of 
adiponectin, the adipocyte-derived hormone, has been shown 
zTable 2z
Biomarkers of Inflammation*
Variable Metabolic Syndrome (n = 123) Control Subjects (n = 91) P†
hsCRP (mg/L) 4.7 (2.9, 6.3) 1.7 (0.6, 4.2) <.0001
Total adiponectin (µg/mL) 5.1 (3.6, 6.7) 7.0 (4.7, 10.4) <.0001
HMW adiponectin (µg/mL) 2.0 (2.2, 3.5) 3.4 (2, 5.7) <.0001
MMW + LMW adiponectin (µg/mL) 2.9 (2.1, 3.5) 3.5 (2.8, 4.4) <.0001
SA 0.42 ± 0.14 0.49 ± 0.13 .0003
Adiponectin/hsCRP ratio 1.2 (0.6, 2.2) 4.6 (1.2, 15) <.0001
HMW adiponectin/hsCRP ratio 0.5 (0.22, 1.1) 2.3 (0.5, 7.2) <.0001
MMW + LMW adiponectin/hsCRP ratio 0.96 ± 0.12 3.89 ± 0.54 <.0001
HMW, high-molecular-weight; hsCRP, high-sensitive C-reactive protein; LMW, low-molecular-weight; MMW, medium-molecular-weight; SA, HMW adiponectin/total 
adiponectin ratio.
* Data are given as mean ± SD or median (25th, 75th percentile). 
† Wilcoxon rank sum test.
zTable 4z
Odds Ratio for Metabolic Syndrome*
 Odds Ratio 95% Confidence Interval Comparison of ROC AUC P
CRP (high) 3.8 2.1-6.8 Reference
Adiponectin (low) 2.5 1.3-4.5 .20
Total adiponectin/CRP 2.6 1.5-4.8 .08
HMW adiponectin/CRP 3.0 1.7-5.4 .33
Non-HMW adiponectin/CRP 3.0 1.6-5.4 .22
AUC, area under the curve; HMW, high-molecular-weight; CRP, C-reactive protein; ROC, receiver operating characteristic.
* 75th percentile cutoff (25th for adiponectin).
zTable 3z
Stratification of Subjects With or Without Metabolic Syndrome by Number of Metabolic Syndrome Components*
                    No. of Components
Variable 0 (n = 33) 1 (n = 35) 2 (n = 23) 3 (n = 66) 4 (n = 35) 5 (n = 22) P† ANOVA
hsCRP (mg/L) 1.9 ± 0.3 3.2 ± 0.5 4.7 ± 0.5 4.8 ± 0.3 5.2 ± 0.8 5.1 ± 0.8 <.0001
Total adiponectin (µg/mL) 10.03 ± 0.83 7.02 ± 0.45 5.61 ± 0.54 5.65 ± 0.33 4.91 ± 0.35 3.01 ±0.29 <.0001
HMW adiponectin (µg/mL) 5.88 ± 0.64 3.57 ± 0.33 2.57 ± 0.36 2.70 ± 0.25 2.18 ± 0.25 1.06 ± 0.16 <.0001
MMW + LMW adiponectin (µg/mL) 4.15 ± 0.23 3.46 ± 0.16 3.04 ± 0.20 2.95 ± 0.13 2.73 ± 0.18 1.96 ± 0.19 <.0001
SA 0.54 ± 0.02 0.47 ± 0.02 0.41 ± 0.02 0.43 ± 0.02 0.42 ± 0.03 0.35 ± 0.03 .0001
Adiponectin/hsCRP ratio 15.5 ± 3.1 8.1 ± 1.8 2.8 ± 0.6 1.9 ± 0.3 1.6 ± 0.2 0.7 ± 0.1 <.0001
HMW adiponectin/hsCRP ratio 8.68 ± 1.81 4.18 ± 1.04 1.23 ± 0.29 0.95 ± 0.15 0.63 ± 0.09 0.23 ± 0.04 <.0001
MMW + LMW adiponectin/ 6.82 ± 1.40 3.93 ± 0.83 1.58 ± 0.31 1.02 ± 0.16 0.89 ± 0.16 0.43 ± 0.09 <.0001 
  hsCRP ratio 
ANOVA, analysis of variance; HMW, high-molecular-weight; hsCRP, high-sensitive C-reactive protein; LMW, low-molecular-weight; MMW, medium-molecular-weight; SA, 
HMW adiponectin/total adiponectin ratio.
* Data are given as mean ± SEM.
† Kruskal-Wallis test.
Am J Clin Pathol  2008;129:815-822     819
819     DOI: 10.1309/RN84K51B2JJY1Y0B     819
© American Society for Clinical Pathology
Clinical Chemistry / oRiginAl ARticle
to be lower in MetS. Indeed, adiponectin concentrations cor-
relate negatively with insulin resistance and adiposity. Recent 
lines of evidence indicate that oligomers of adiponectin, espe-
cially the HMW form, may be more important for the predic-
tion of MetS or insulin resistance than measurements of total 
adiponectin.30 Prediction of MetS, defined by the presence of 
a cluster of metabolic abnormalities, including impaired glu-
cose metabolism, increased central adiposity, dyslipidemia, 
and hypertension, seems to be important because of its asso-
ciation with the subsequent development of type 2 diabetes 
and cardiovascular disease. Developing a robust laboratory-
based biomarker that will capture the various features of 
MetS instead of examining its individual components would 
be ideal from a population standpoint for screening and for 
testing novel therapeutic strategies.
Because CRP concentrations are higher and adiponectin 
concentrations are lower in MetS, we hypothesized that the 
ratio would emerge as a robust biomarker of MetS. Also, there 
seems to be cross-talk between CRP and adiponectin, with a 
recent article showing that CRP inhibits adiponectin expres-
sion and secretion from adipocytes in vitro.31 In the present 
cross-sectional study of 214 subjects with and without MetS, 
we found that hsCRP concentrations were significantly and 
progressively higher and concentrations of adiponectin and 
its oligomers and the ratio of hsCRP to adiponectin and its 
oligomers were significantly and progressively lower as the 
number of features of MetS present increased. Furthermore, 
measurement of the hsCRP level alone was equivalent to mea-
suring the level of adiponectin or its oligomers and the ratio of 
hsCRP to adiponectin or its oligomers.
As previously demonstrated in several large trials,4,5,8,9 
concentrations of hsCRP, an acute phase marker of inflamma-
tion, were higher in subjects with MetS. In particular, hsCRP 
concentrations exhibited a positive, significant, independent 
relationship with an increased number of features of MetS. 
In previous studies, strong associations between CRP and 
measures of body fat (BMI and waist circumference) and 
measures of insulin resistance (insulin sensitivity index, fast-
ing insulin, and proinsulin) have been reported.4,5,8,10
MetS is also characterized by low adiponectin 
concentrations.19,32,33 Adiponectin concentrations in plasma 
are often found to be positively correlated with HDL-C and 
insulin sensitivity, whereas inverse correlations with adiposity 
(particularly central adiposity), triglyceride levels, and hsCRP 
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zFigure 1z Receiver operating characteristic (ROC) curves for high-sensitive C-reactive protein (hsCRP) vs ratio (A; ROC area 
under the curve [AUC] = 0.50), ratio alone (B; ROC AUC = 0.752; 95% confidence interval [CI], 0.684-0.821), hsCRP alone (C; 
ROC AUC = 0.738; 95% CI, 0.668-0.808), and adiponectin alone (D; ROC AUC = 0.692; 95% CI, 0.619-0.765) for metabolic 
syndrome. TA, total adiponectin.
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concentrations have also been observed.34-36 However, atten-
tion has been focused on the different multimeric forms of 
adiponectin11,23 because these different molecular species are 
capable of activating different signaling pathways in muscle, 
liver, and endothelium.32,33,37 The HMW form is of particular 
interest for MetS because administration of the HMW form, 
but not the MMW form, reduces the blood glucose level 
in insulin-resistant, adiponectin-deficient mice.11 Because 
insulin resistance and/or low-grade inflammation are likely 
to be important underlying defects in MetS, we hypothesized 
that HMW adiponectin may be more indicative of MetS than 
measures of total or non-HMW (MMW + LMW) adiponectin. 
Furthermore, because we found that low adiponectin or HMW 
adiponectin and high hsCRP concentrations were indepen-
dently associated with features of MetS, we hypothesized 
that the ratio of hsCRP to adiponectin or its oligomers may 
provide better predictive value for MetS.
Indeed, several lines of evidence point to the role of 
HMW adiponectin as a better predictor of insulin sensitiv-
ity. Swarbrick et al23 demonstrated that HMW adiponectin 
changes before total adiponectin in response to weight loss, 
and increases of HMW adiponectin are more closely related 
to the improvement of HOMA-IR and fasting insulin than 
changes of the LMW and MMW oligomers. Pajvani et al22 
reported that changes in HMW adiponectin predict thiazoli-
dinedione-mediated improvements in insulin sensitivity. Basu 
et al30 recently reported that HMW adiponectin and the HMW 
adiponectin/total adiponectin ratio are lower in people with 
diabetes than in people who do not have diabetes.
Furthermore, Fisher et al32 demonstrated the importance 
of the SA index as a better determinant of glucose intoler-
ance than measurements of total adiponectin, suggesting that 
HMW adiponectin is the active form of the protein. On the 
other hand, Polak et al33 recently reported the absence of any 
correlation between changes in adiponectin complexes and 
indices of insulin sensitivity in diet-induced weight loss in 20 
overweight or obese women who underwent 12 weeks of a 
low caloric diet. Abbasi et al38,39 reported parallel improve-
ments in insulin resistance in thiazolidinedione-treated sub-
jects, along with changes in the levels of total adiponectin 
and several specific adiponectin complexes; however, neither 
circulating adiponectin concentrations nor multimeric com-
plexes changed in association with enhanced insulin sensitiv-
ity after moderate weight loss in 12 insulin-resistant, obese 
people.39 However, most of the studies detailed herein were 
performed in subjects with diabetes and also had sample sizes 
too small for examining the predictive power of adiponectin 
multimers for MetS.
Our findings contrast with those of Hara et al,40 who 
found that SA was more predictive than total adiponectin 
for the presence of MetS. The authors did not evaluate the 
absolute amount of HMW adiponectin as a predictor of MetS 
and did not examine the potential relationship of adiponectin 
oligomers to individual MetS components. Even though the 
assay used was identical,28 in the present study, we found SA 
to be less indicative of MetS than any of the other adiponectin 
measurements.
There are several possible reasons for the discrepancies 
observed. First, the patients studied by Hara et al40 had dia-
betes or were undergoing coronary angiography and so were 
likely to be in worse health than the subjects in the present 
study and receiving concomitant medications that could have 
affected the outcome of the study. In our study, we had a large 
sample and did not include patients with diabetes or people 
taking antidiabetic medications. Second, the subjects in the 2 
studies are not directly comparable because the subjects stud-
ied by Hara et al40 had a lower average BMI (22-24 kg/m2 vs 
30-36 kg/m2 in the present study) and were older. Also, the 
present study goes further in assessing not only adiponectin 
oligomers but also the ratio of hsCRP to adiponectin or its 
oligomers for predicting MetS.
In this study, although adiponectin concentrations, adi-
ponectin oligomers, and ratios of hsCRP to adiponectin or 
its oligomers were significantly and progressively decreased 
with an increase in the number of features of MetS present, 
we had hypothesized that the ratio of hsCRP to adiponectin or 
its oligomers would be superior to either alone in predicting 
MetS; however, the OR and ROC curve analyses indicated 
that measurement of hsCRP is equivalent to measurement 
of adiponectin or its oligomers and the ratios of hsCRP to 
adiponectin or its oligomers in predicting MetS. Although a 
CRP cutoff of 3 mg/L provides low specificity (64%), the sen-
sitivity is greater (73%) and seems to be slightly better than 
that of adiponectin and its oligomers. Furthermore, laboratory 
measurements that define MetS, such as triglyceride levels, 
have huge biologic variability (>25%), and HDL assays are 
far from optimum. Although adiponectin measurements need 
to be standardized, especially with respect to its oligomers, 
before they can be used in clinical practice, the measure-
ment of hsCRP alone, which is automated and available on 
most clinical chemistry platforms, is standardized with a CV 
of less than 10%. Furthermore, measurement of the hsCRP 
concentration provides an objective and adjunctive biochemi-
cal marker for MetS that predicts cardiovascular events in 
this population that can be used to screen large populations 
for natural history of the disease and to assess response to 
therapeutic interventions targeting MetS, such as therapeutic 
lifestyle changes and pharmacotherapies.
hsCRP seems to be a robust biomarker for MetS. 
Ongoing studies with adiponectin oligomers, resistin, visfa-
tin, and retinol binding protein-4 will hopefully help define a 
multimarker panel with greater sensitivity and specificity to 
identify MetS.
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